Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind double-dummy study of upadacitinib versus dupilumab in adults with moderate to severe atopic dermatitis
MOH_2019-04-02_004933Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Upadacitinib arm with Dupilumab arm (2 arms). Started Mar 2019; status: completed.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2019-04-02_004933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-02_004933.